BoA Downgrades Ligand Pharma to 'Market Perform'

Analyst Michael King says sales of the drug maker's pain treatment were well below his estimates

Banc of America downgraded Ligand Pharmaceuticals (LGND ) to market perform from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.